DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clofarabine in refractory Langerhans cell histiocytosis.

Author(s): Rodriguez-Galindo C, Jeng M, Khuu P, McCarville MB, Jeha S

Affiliation(s): Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. carlos.rodriguez-galindo@stjude.org

Publication date & source: 2008-11, Pediatr Blood Cancer., 51(5):703-6.

Publication type: Case Reports; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Patients with multi-system Langerhans cell histiocytosis (LCH) who progress on frontline therapy have a dismal outcome. Responses to cladribine have been reported in relapsed LCH, but there are no well defined salvage regimens for LCH is refractory to therapy. The next generation deoxyadenosine analog, clofarabine, has demonstrated activity in patients with leukemia that is refractory to salvage regimens, including other nucleotide congeners; however, no experience exist on the use of clofarabine in LCH. In this report we describe significant single agent activity of clofarabine in disseminated LCH refractory to salvage regimens, including cladribine. (c) 2008 Wiley-Liss, Inc.

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017